Tharimmune, Inc. (THAR)
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.
Address
1200 ROUTE 22 EAST
BRIDGEWATER, NJ 08807
Founded
2017
Number of Employees
2
Website
http://tharimmune.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)